– Eko announced the FDA has granted “breakthrough status” for an algorithm that could provide an easily accessible screening test for heart failure during routine physical exams.
– This designation is awarded to novel innovations that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases.
– Heart failure is often left untreated until it’s too late due to costs, inaccessibility to echocardiogram testing, or misdiagnosis. With nearly six million people affected by this condition, and many options available, early diagnosis is the key to life-prolonging treatments.
Eko, a digital health company applying artificial intelligence (AI) in the fight against heart disease, today announced the U.S. Food and Drug Administration (FDA) has granted the company breakthrough status for a novel ECG-based algorithm that could provide an easily accessible screening test for heart failure. The algorithm analyzes 15 seconds of ECG data collected from the Eko DUO digital stethoscope during a physical exam and helps identify reduced Left Ventricular Ejection Fraction (LVEF), a measure commonly used to diagnose patients with heart failure.
Heart Failure Often Detected Too Late
Heart failure affects about 5.7 million people in the U.S. alone and is most commonly detected by echocardiogram imaging tests that are not normally conducted during a physical exam. Because of limited access to echocardiography, heart failure is frequently diagnosed late, making life-prolonging treatment more challenging.
Eko’s Low Ejection Fraction Algorithm
“A low ejection fraction means that the heart pump is weak, which can lead to shortness of breath, swelling, exercise intolerance, or sudden death, so it is important to identify, as many treatments exist,” said Dr. Paul Friedman, chair of the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn. “This technology gives physicians a tool to detect heart disease earlier, and before it develops into a more serious illness. In effect, by embedding the technology in a commonly used clinical tool – the stethoscope – all caregivers carry some of the diagnostic prowess of an expert cardiologist with them.”
Eko’s low ejection fraction algorithm employs a deep neural network developed in collaboration with Mayo Clinic. The algorithm was first announced in a landmark publication in Nature Medicine in January 2019. In further clinical studies at Mayo Clinic, the DUO combined with the AI algorithm was able to detect ejection fraction < 35% with an area under the curve (AUC) of 0.90.
Impact of FDA Breakthrough Device Designation
The FDA’s Breakthrough Device program helps patients gain more timely access to medical devices by expediting their development, assessment, and review, while preserving the statutory standard of reasonable assurance of safety and effectiveness for premarket approval and the statutory standards for granting a de novo request.
FDA Breakthrough Device designation helps accelerate the algorithm’s regulatory review and is only awarded to novel innovations that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases. This status does not mean the algorithm has received FDA clearance.
“The Breakthrough Device designation recognizes the vast unmet clinical needs in identifying heart failure early in patients, whether it be due to cost, inaccessibility, or misdiagnosis,” said Connor Landgraf, CEO, and co-founder of Eko. “We look forward to working with the FDA to bring this algorithm to patients and to give clinicians a new tool to screen for low ejection fraction.”
Peer-Reviewed Data Already Available
Eko’s low ejection fraction algorithm employs a deep neural network developed in collaboration with Mayo Clinic. The algorithm was first announced in a landmark publication in Nature Medicine in January 2019. In further clinical studies at Mayo Clinic, the DUO combined with the AI algorithm was able to detect ejection fraction < 35% with an area under the curve (AUC) of 0.90.
Mayo Clinic and Dr. Friedman have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
